Pharmacologic disruption of the interaction between GFI1 and LSD1, a major scaffolding and catalytic component of these complexes, induces differentiation in AML and has highlighted GFI1 and CoREST complexes as important therapeutic targets for the treatment of AML [47–50]. The gene discussed is KDM1A; the disease is acute myeloid leukemia.